Role of NAFLD on the Health Related QoL Response to Lifestyle in Patients With Metabolic Syndrome: The PREDIMED Plus Cohort.
Autor: | Martínez-Urbistondo D; Internal Medicine Department, Hospital HM Sanchinarro, HM Hospitales, Madrid, Spain., San Cristóbal R; Cardiometabolic Nutrition Group, Precision Nutrition and Cardiometabolic Health Program, Instituto Madrileño de Estudios Avanzados (IMDEA) Food, Centro de Excelencia en Investigación (CEI) Universidad Autónoma de Madrid (UAM) + Centro Superior de Investigaciones Científicas (CSIC), Madrid, Spain., Villares P; Internal Medicine Department, Hospital HM Sanchinarro, HM Hospitales, Madrid, Spain., Martínez-González MÁ; Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain.; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, United States., Babio N; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Universitat Rovira i Virgili, Departament de Bioquímica i biotecnologia, Unitat de Nutrició Humana, Reus, Spain.; Institut d'Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari San Joan de Reus. Human Nutrition unit, Reus, Spain., Corella D; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Preventive Medicine, University of Valencia, Valencia, Spain., Del Val JL; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Cardiovascular Risk and Nutrition Research Group (CARIN), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Ordovás JM; Nutritional Genomics and Epigenomics Group, Precision Nutrition and Obesity Program. Instituto Madrileño de Estudios Avanzados (IMDEA) Food, Centro de Excelencia en Investigación (CEI) Universidad Autónoma de Madrid (UAM) + Centro Superior de Investigaciones Científicas (CSIC), Madrid, Spain.; Nutrition and Genomics Laboratory, Jean Mayer United States Department of Agriculture (JM_USDA) Human Nutrition Research Center on Aging, Tufts University, Boston, MA, United States., Alonso-Gómez ÁM; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Vitoria-Gasteiz, Spain., Wärnberg J; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Nursing, School of Health Sciences, University of Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain., Vioque J; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.; Instituto de Investigación Sanitaria y Biomédica de Alicante. Universidad Miguel Hernández (ISABIAL-UMH). Alicante, Spain., Romaguera D; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR). Health Research Institute of the Balearic Islands (IdISBa), University Hospital Son Espases (HUSE), Palma de Mallorca, Spain., López-Miranda J; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain., Estruch R; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Internal Medicine, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain., Tinahones FJ; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Endocrinology, Instituto de Investigación Biomédica de Málaga (IBIMA), Virgen de la Victoria Hospital, University of Málaga, Málaga, Spain., Lapetra J; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain., Serra-Majem JL; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Research Institute of Biomedical and Health Sciences Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), University of Las Palmas de Gran Canaria, Preventive Medicine Service, Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, Las Palmas, Spain., Bueno-Cavanillas A; Department of Nursing, School of Health Sciences, University of Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.; Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain., Tur JA; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, Palma de Mallorca, Spain., Marcos A; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.; Institute of Biomedicine (IBIOMED), University of León, León, Spain., Pintó X; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain., Delgado-Rodríguez M; Department of Nursing, School of Health Sciences, University of Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.; Departamento de Ciencias de la Salud, Centro de Estudios Avanzados en Olivar y Aceites de Oliva, Universidad de Jaén, Jaén, Spain., Matía-Martín P; Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain., Vidal J; Biomedical Research Centre for Diabetes and Metabolic Diseases Network (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Endocrinology and Nutrition Service, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain., Vázquez C; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Endocrinology and Nutrition, Hospital Fundación Jimenez Díaz, Instituto de Investigaciones Biomédicas IISFJD. University Autónoma, Madrid, Spain., Ros E; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Endocrinology and Nutrition Service, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain., Bullón Vela MV; Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain.; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain., Palau A; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Universitat Rovira i Virgili, Departament de Bioquímica i biotecnologia, Unitat de Nutrició Humana, Reus, Spain.; Institut d'Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari San Joan de Reus. Human Nutrition unit, Reus, Spain., Masagué M; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Cardiovascular Risk and Nutrition Research Group (CARIN), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Abete I; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Nutrition, Food Sciences and Physiology, University of Navarra, Pamplona, Spain., Moreno-Rodríguez A; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Vitoria-Gasteiz, Spain., Candela-García I; Centro de Salud San Pola, Alicante, Spain., Konieczna J; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR). Health Research Institute of the Balearic Islands (IdISBa), University Hospital Son Espases (HUSE), Palma de Mallorca, Spain., García-Ríos A; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain., Juárez OL; Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain.; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain., Martín P; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Universitat Rovira i Virgili, Departament de Bioquímica i biotecnologia, Unitat de Nutrició Humana, Reus, Spain.; Institut d'Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari San Joan de Reus. Human Nutrition unit, Reus, Spain., Goday A; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Cardiovascular Risk and Nutrition Research Group (CARIN), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Zulet MÁ; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Nutrition, Food Sciences and Physiology, University of Navarra, Pamplona, Spain., Vaquero-Luna J; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Vitoria-Gasteiz, Spain., Orea MDCS; Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain.; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain., Megías I; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Universitat Rovira i Virgili, Departament de Bioquímica i biotecnologia, Unitat de Nutrició Humana, Reus, Spain.; Institut d'Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari San Joan de Reus. Human Nutrition unit, Reus, Spain., Baltasar E; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Cardiovascular Risk and Nutrition Research Group (CARIN), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Martínez JA; Cardiometabolic Nutrition Group, Precision Nutrition and Cardiometabolic Health Program, Instituto Madrileño de Estudios Avanzados (IMDEA) Food, Centro de Excelencia en Investigación (CEI) Universidad Autónoma de Madrid (UAM) + Centro Superior de Investigaciones Científicas (CSIC), Madrid, Spain.; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII). Madrid, Spain.; Department of Nutrition, Food Sciences and Physiology, University of Navarra, Pamplona, Spain., Daimiel L; Nutritional Control of the Epigenome Group. Precision Nutrition and Obesity Program. Instituto Madrileño de Estudios Avanzados (IMDEA) Food, Centro de Excelencia en Investigación (CEI) Universidad Autónoma de Madrid (UAM) + Centro Superior de Investigaciones Científicas (CSIC), Madrid, Spain. |
---|---|
Jazyk: | angličtina |
Zdroj: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2022 Jun 29; Vol. 13, pp. 868795. Date of Electronic Publication: 2022 Jun 29 (Print Publication: 2022). |
DOI: | 10.3389/fendo.2022.868795 |
Abstrakt: | Objective: To evaluate the effect of Non-alcoholic fatty liver disease (NAFLD) status in the impact of lifestyle over Health-related quality of life (HRQoL) in patients with metabolic syndrome (MetS). Methods: Baseline and 1 year follow up data from the PREDIMED-plus cohort (men and women, 55-75 years old with overweight/obesity and MetS) were studied. Adherence to an energy-restricted Mediterranean Diet (er-MeDiet) and Physical Activity (PA) were assessed with a validated screeners. Hepatic steatosis index (HSI) was implemented to evaluate NAFLD while the SF-36 questionnaire provided HRQoL evaluation. Statistical analyses were performed to evaluate the influence of baseline NAFLD on HRQoL as affected by lifestyle during 1 year of follow up. Results: Data from 5205 patients with mean age of 65 years and a 48% of female participants. Adjusted linear multivariate mixed regression models showed that patients with lower probability of NAFLD (HSI < 36 points) were more responsive to er-MeDiet (β 0.64 vs β 0.05 per er-MeDiet adherence point, p< 0.01) and PA (β 0.05 vs β 0.01 per MET-h/week, p = 0.001) than those with high probability for NAFLD in terms Physical SF-36 summary in the 1 year follow up. 10 points of er-MeDiet adherence and 50 MET-h/week were thresholds for a beneficial effect of lifestyle on HRQoL physical domain in patients with lower probability of NAFLD. Conclusion: The evaluation of NAFLD by the HSI index in patients with MetS might identify subjects with different prospective sensitivity to lifestyle changes in terms of physical HRQoL (http://www.isrctn.com/ISRCTN89898870). Competing Interests: Author JS-S reports grants from CIBEROBN, ISCIII (Spain), during the conduct of the study; non-financial support from Nut and Dried Fruit Foundation, personal fees from Instituto Danone Spain, grants from Nut and Dried Fruit Foundation to this institution, grants from Eroski Distributors and personal fees from Nut and Dried Fruit Foundation, outside the submitted work. Moreover, he gratefully acknowledges the financial support by ICREA under the ICREA Academia program. The author DR declares the funding of the AstraZeneca Young Investigators Award in Category of Obesity and T2D 2017. The author RS-C acknowledges financial support from the Juan de la Cierva Program Training Grants of the Spanish State Research Agency of the Spanish Ministerio de Ciencia e Innovación y Ministerio de Universidades (FJC2018-038168- I). The author ER reports grants, personal fees, non-financial support and other from California Walnut Commission, grants, personal fees, non-financial support and other from Alexion, personal fees, non-financial support and other from Ferrer International, personal fees from Amarin, personal fees, non-financial support and other from Danone, outside the submitted work. The author JL-M reports personal fees and non-financial support from AMGEN, personal fees and non-financial support from SANOFI, personal fees from MSD, personal fees from Laboratorios Dr. Esteve, and personal fees from NOVO-NORDISK, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Martínez-Urbistondo, San Cristóbal, Villares, Martínez-González, Babio, Corella, del Val, Ordovás, Alonso-Gómez, Wärnberg, Vioque, Romaguera, López-Miranda, Estruch, Tinahones, Lapetra, Serra-Majem, Bueno-Cavanillas, Tur, Marcos, Pintó, Delgado-Rodríguez, Matía-Martín, Vidal, Vázquez, Ros, Bullón Vela, Palau, Masagué, Abete, Moreno-Rodríguez, Candela-García, Konieczna, García-Ríos, Juárez, Martín, Goday, Zulet, Vaquero-Luna, Orea, Megías, Baltasar, Martínez and Daimiel.) |
Databáze: | MEDLINE |
Externí odkaz: |